Investment Rating - The report maintains an "Outperform" rating for the company [3][8][13] Core Insights - The company achieved a revenue growth of 13.5% in the first half of 2024, with significant contributions from recycled products [2][10] - The gross margin for the first half of 2024 was reported at 94.9%, with a net profit margin of 67.7%, reflecting improved efficiency in sales and management expenses [11][12] - The company has a robust pipeline of products under development, including various medical and aesthetic solutions, which are expected to drive future growth [12][13] Financial Performance - For the first half of 2024, the company reported a revenue of 1.66 billion yuan, with net profit attributable to the parent company reaching 1.12 billion yuan, marking a 16.4% increase [11][12] - The projected revenues for 2024 and 2025 are estimated at 3.50 billion yuan and 4.36 billion yuan, respectively, with year-on-year growth rates of 21.9% and 24.6% [13] - The net profit for 2024 and 2025 is expected to be 2.29 billion yuan and 2.88 billion yuan, reflecting growth rates of 23.4% and 23.6% [13] Market Position and Valuation - The company is recognized as an industry leader with strong brand and channel advantages, justifying a target price of HKD 341.34 per share based on a 36x PE for 2025 [13] - The current market capitalization is approximately 41.03 billion yuan (5.77 billion USD) [3][8] Product Development - The company is advancing several key products, including Type A botulinum toxin and modified hyaluronic acid gel, which are in various stages of regulatory approval [12][13] - The investment in the "Beautiful Health Industrialization Innovation Construction Project" aims to enhance production capacity and product offerings [11][12]

公司报告 | 半年报点评 24Q2 归母净利润同增 8%，高基数稳健过渡 爱美客（300896） 证券研究报告 2024 年 09 月 06 日 投资评级 行业 美容护理/医疗美容 6 个月评级 买入（维持评级） 当前价格 136.77 元 目标价格 元 事件：公司发布 24 半年报，24H1 实现营业收入 16.57 亿元/yoy+13.53%， 归母 净利 润 11.21 亿元/yoy+16.35%， 扣 非归 母净 利润 10.89 亿元 /yoy+16.58%，24Q2 实现营业收入 8.49 亿元/yoy+2.35%，归母净利润 5.93 亿元/yoy+8.03%，扣非归母净利润 5.6 亿元/yoy+2.46%。 业绩分析： ■24H1 溶液类注射产品营收 9.8 亿元，同增 11.7%，凝胶类注射产品营收 6.5 亿元，同增 14.6%。 ■加快成果转化，质效双增促长期发展。"美丽健康产业化创新建设项目" 进展顺利，项目建成后，将进一步扩大公司目前现有产品的产能，丰富新 产品供给，提升公司的对外合作能力，进一步满足医美市场需求。 ■聚焦产业布局，研发创新驶入快车道。研发投入 1.3 亿，同增 2 ...

[Table_Industry] 爱美客（300896.SZ）/美护 证券研究报告/公司点评 2024 年 9 月 05 日 | --- | |-------------------------------------------------------------------| | | | 市场价格： 137.22 元 | | [Table_ 分析师：郑澄怀 Authors] 执业证书编号： S0740524040004 | | ： zhengch@zts.com.cn | 分析师：张前 执业证书编号：S0740524080002 Email：zhangq08@zts.com.cn [Table_Profit] 基本状况 | --- | --- | |-------------------|--------| | | | | 总股本 ( 亿股 ) | 3.02 | | 流通股本 ( 亿股 ) | 2.08 | | 市价 ( 元 ) | 137.22 | | 市值 ( 亿元 ) | 415 | | 流通市值 ( 亿元 ) | 286 | [Table_QuotePic] 股价与行业-市场走势对比 公司持有该股 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark index within the next six months [10]. Core Insights - The company, Aimeike (300896.SZ), achieved a revenue of 1.657 billion yuan in the first half of 2024, representing a year-on-year growth of 13.53%, with a net profit attributable to shareholders of 1.121 billion yuan, up 16.35% [1]. - In Q2 2024, the company reported a revenue of 849 million yuan, a slight increase of 2.35%, and a net profit of 593 million yuan, up 8.03% [1]. - The gross margin stood at 94.91%, with a slight decline of 0.5 percentage points year-on-year, while the net margin improved by 1.82 percentage points to 67.68% due to effective cost control [1]. - The company has a rich pipeline of products under development, including ten Class III medical devices approved by the National Medical Products Administration [1]. - The company is focusing on building a platform in the medical aesthetics sector, with various products in different stages of development, including treatments for dynamic wrinkles and chronic weight management [1]. Summary by Relevant Sections Financial Performance - For the first half of 2024, the company reported a revenue of 1.657 billion yuan and a net profit of 1.121 billion yuan, with Q2 figures showing a revenue of 849 million yuan and a net profit of 593 million yuan [1]. - The company’s revenue projections for 2024-2026 have been adjusted to 3.486 billion, 4.328 billion, and 5.483 billion yuan respectively, with net profit estimates revised to 2.267 billion, 2.826 billion, and 3.571 billion yuan [2]. Product Development - The company’s product categories show that gel products are growing faster than solution products, with gel product revenue reaching 649 million yuan, a growth of 14.57% [1]. - The company is developing a diverse range of products, including a modified hyaluronic acid gel for chin augmentation and a minoxidil topical solution, among others [1]. Market Positioning - The company leverages its product pipeline and marketing strategies to enhance its market presence, focusing on differentiated product functionalities and competitive marketing tactics [1]. - The company has established advantages in product offerings, marketing strategies, and institutional partnerships, enhancing its overall competitiveness in the medical aesthetics market [1].

Q2 基本符合预期，中长期成长动能充足 买入 （维持） 核心观点 ⚫ 公司发布 24H1 中报，实现营业收入 16.6 亿，同比增长 14%，实现归母净利润 11.2 亿，同比增长 16%，其中 24Q2 的收入和归母净利润分别同比增加 2.4%和 8%，在 去年同期的高基数上（23Q2 收入和盈利同比分别增长 83%和 77%）基本符合预 期。中报公司经营净现金 11.51 亿元，同比增长 17.76%，继续保持优良水平。 ⚫ 分产品来看：1）溶液类产品：24H1 实现收入 9.76 亿，同比增长 11.7%，毛利率同 比下降 1.1pct 至 94%，我们判断由于低毛利率的水光产品占比提升所致。2）凝胶 类产品：24H1 实现收入 6.49 亿，同比增长 14.6%，我们判断天使系列继续优异增 长，毛利率同比增长 0.6pct 至 98%。3）面部埋植线：24H1 实现收入 348 万元，同 比增长 16%。 ⚫ 盈利能力稳中有升，拆分来看：1）毛利率：24H1 毛利率同比下降 0.5pct 至 94.9%；2）费用率：24H1 销售、管理和研发费用率分别增长-1.7pct、-1.4pct 和 0.4pc ...

证券研究报告 公司点评 爱美客(300896.SZ) 2024 年 08 月 23 日 评级 买入 | --- | --- | |---------------------|---------------| | | 维持 | | 交易数据 | | | 当前价格（元） | 141.30 | | 52 周价格区间（元） | 141.30-453.10 | | 总市值（百万） | 42734.50 | | 流通市值（百万） | 29456.10 | | 总股本（万股） | 30243.80 | | 流通股（万股） | 20846.50 | 涨跌幅比较 爱美客 美容护理 -51% -31% -11% 9% 29% 2023-08 2023-11 2024-02 2024-05 2024-08 % 1M 3M 12M 爱美客 -16.86 -36.75 -52.77 美容护理 -11.01 -25.85 -38.38 张曦月 分析师 执业证书编号:S0530522020001 zhangxiyue@hnchasing.com 相关报告 1 爱美客（300896.SZ）2024 年一季报点评：业 绩增长符合预期，期待核心 ...

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 189 CNY, compared to the current price of 143.87 CNY [2][3]. Core Insights - The company achieved a revenue of 1.657 billion CNY in H1 2024, representing a year-on-year growth of 13.53%. The gross profit was 1.573 billion CNY with a gross margin of 94.91%, a slight decrease of 0.50 percentage points year-on-year. The net profit attributable to the parent company was 1.121 billion CNY, up 16.35% year-on-year, with a net profit margin of 67.65%, an increase of 1.64 percentage points year-on-year [2]. - In Q2 2024, the company reported revenue of 849 million CNY, a growth of 2.35% year-on-year. The gross profit was 809 million CNY with a gross margin of 95.26%, down 0.24 percentage points year-on-year. The net profit attributable to the parent company was 593 million CNY, up 8.03% year-on-year, with a net profit margin of 69.92%, an increase of 3.68 percentage points year-on-year [2][3]. - The company is focusing on the launch of its product pipeline, with expectations for multiple products to be approved post-2025, enhancing its product matrix and competitive advantage [3]. Financial Summary - For the fiscal years 2023A to 2026E, the total revenue is projected to grow from 2.869 billion CNY in 2023 to 5.601 billion CNY in 2026, with year-on-year growth rates of 48.0%, 22.3%, 26.9%, and 25.7% respectively [4]. - The net profit attributable to the parent company is expected to increase from 1.858 billion CNY in 2023 to 3.588 billion CNY in 2026, with corresponding growth rates of 47.1%, 22.8%, 25.1%, and 25.7% [4]. - The earnings per share (EPS) is forecasted to rise from 6.14 CNY in 2023 to 11.86 CNY in 2026, with a price-to-earnings (P/E) ratio decreasing from 23 to 12 over the same period [4].

Investment Rating - The report maintains a "Buy-B" rating for the company, indicating an expected price increase exceeding the relative benchmark index by more than 15% [1][9]. Core Insights - The company's net profit growth rate outpaces revenue growth, with improvements in expense management noted [1]. - The company has a rich pipeline of products under research, including the injectable type A botulinum toxin, which has entered the registration application stage, and two non-invasive skin rejuvenation devices in collaboration with Jeisys from South Korea [2][5]. - The projected earnings per share (EPS) for 2024-2026 are 7.58, 9.69, and 11.90 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 19, 14.9, and 12.1 times [2][5]. Financial Performance Summary - For the first half of 2024, the company achieved revenue of 1.657 billion yuan, a year-on-year increase of 13.53%, and a net profit of 1.12 billion yuan, up 16.35% [4]. - The second quarter of 2024 saw revenue of 849 million yuan, growing 2.35% year-on-year, and a net profit of 593 million yuan, an increase of 8.03% [4]. - The gross margin for the first half of 2024 was 94.91%, with a net margin of 67.65%, reflecting stable profit levels and improved expense ratios [5]. Product and Market Insights - Solution products continue to be the main revenue contributor, with injection solutions generating 976 million yuan in revenue, up 11.65%, and gel products reaching 649 million yuan, a 14.57% increase [5]. - The company is progressing well with its research projects, with several products at various stages of clinical trials and registration [5][8]. Financial Projections - Revenue projections for 2024-2026 are 3.596 billion, 4.623 billion, and 5.705 billion yuan, respectively, with net profit estimates of 2.292 billion, 2.930 billion, and 3.600 billion yuan [6][8]. - The company is expected to maintain a gross margin of around 95% and a net margin of approximately 63% over the next few years [7][8].

本报告仅供 Choice 东方财富 使用，请勿传阅。 2024 年 08 月 22 日 爱美客(300896.SZ) 24H1 业绩保持增长，盈利能力不断提 升 爱美客发布 2024 年半年度报告： 1）2024 年上半年，公司实现营业收入 16.57 亿元/同比+13.53%，归 母净利润 11.21 亿元/同比+16.35%，归母扣非净利润 10.89 亿元/同 比+16.58%。经营性现金流量净额 11.50 亿元/同比+17.76%。 2）单二季度，公司实现营业收入 8.49 亿元/同比+2.35%/环比+5.04%， 归母净利润 5.93 亿元/同比+8.03%/环比+12.52%，扣非归母净利润 5.60 亿元/同比+2.46%/环比+6.02%。 盈利能力持续提升，研发费用投入加大： 1）2024 年上半年，公司归母净利率 67.65%/+1.64pcts，毛利率 94.91%/-0.50pct，销售费用率 8.52%/-1.67pcts，管理费用率 4.09%/-1.40pcts，研发费用率 7.59%/+0.44pct。公司盈利能力提升 主要得益于费用管控得当。 2）单二季度，公司归母净利率 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4]. Core Views - The company experienced a slowdown in growth in Q2 2024, attributed to a high base effect. The revenue for H1 2024 was CNY 1.657 billion, a year-on-year increase of 13.5%, while Q2 revenue was CNY 849 million, up 2.3% [4]. - The company is a leader in the medical beauty sector, with a diversified product matrix expected to support long-term growth. The valuation is considered reasonable, maintaining the "Buy" rating [4]. - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of CNY 2.298 billion, CNY 2.975 billion, and CNY 3.658 billion respectively, with corresponding EPS of CNY 7.60, CNY 9.84, and CNY 12.10 [4]. Financial Performance - In H1 2024, the solution and gel products generated revenues of CNY 976 million (up 11.6%) and CNY 649 million (up 14.6%) respectively. The facial implant line achieved revenue of CNY 3.48 million, a year-on-year increase of 16.1% [5]. - The gross margin for H1 2024 was 94.9%, with a slight decrease of 0.5 percentage points. The gross margins for solution and gel products were 94.0% and 98.0% respectively [5]. - The overall expense ratio showed improvement, with sales, management, R&D, and financial expense ratios at 8.5% (-1.7pct), 4.1% (-1.4pct), 7.6% (+0.4pct), and -1.4% (+0.5pct) respectively [5]. Product Development and Future Growth - Existing products like "Hi Body" and "Ru White Angel" are steadily growing, enhancing brand influence. The pipeline includes several products expected to launch soon, such as Bonida 2.0 and a botulinum toxin application [6]. - The company has signed an exclusive distribution agreement with Jeisys from South Korea to expand its offerings in energy-based devices, which is expected to complement existing products [6]. - The "Beautiful Health Industry Innovation Construction Project" is progressing well, which will further expand production capacity and enrich supply [6].